COVID-19 – The Cluster Headache Support Group

Risks Associated with COVID-19 Infection and Vaccination for Headache Disorders

On: September 25, 2021

Very little is known about the effect of any COVID-19 vaccine on cluster headache. What little research we have has been done on migraine and tension-type headache. We don’t have answers to all the questions. That doesn’t mean we don’t know anything.Read More →

Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study

By: CHSG Admin

On: September 25, 2021

In: COVID-19, Pathophysiology

With: 0 Comments

The novel coronavirus SARS-CoV-2 causes the infectious disease COVID-19. Newly developed mRNA vaccines can prevent the spread of the virus. Headache is the most common neurological symptom in over 50% of those vaccinated.Read More →

Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine

By: CHSG Admin

On: September 25, 2021

In: COVID-19

With: 0 Comments

This analysis characterizes the immunogenicity profile of galcanezumab, a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and inhibits its activity, in phase 3 migraine trials.Read More →